Skip to content

Evidence-based medicine research of tonifying qi-blood and regulating tendon and vessel on the prevention and treatment of anemia and thrombosis on added effection of enhanced recovery after surgery of total knee arthroplasty

Evidence-based medicine research of tonifying qi-blood and regulating tendon and vessel on the prevention and treatment of anemia and thrombosis on added effection of enhanced recovery after surgery of total knee arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084010
Enrollment
Unknown
Registered
2024-05-09
Start date
2024-05-09
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Test group:The modified Buyang-Huanwu decoction and conventional anticoagulation regimen were used.

Sponsors

Wangjing Hospital of China Academy of Chinese Medicine Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Subjects had to meet all of the following inclusion criteria: (1) 50 years old = enrollment age =80 years old; (2) patients who met the diagnosis of KOA and the indications for TKA; (3) no previous history of thrombosis related diseases within half a year; (4) primary unilateral TKA without contraindication; (5) patients without thrombosis by color Doppler ultrasound before operation; (6) able to cooperate with the follow-up and have good compliance; (7) voluntarily participated in the trial and signed the informed consent form in person.

Exclusion criteria

Exclusion criteria: Subjects could not meet any of the following exclusion criteria: (1) those who did not meet the inclusion criteria; (2) patients with serious underlying medical diseases, including cardiopulmonary dysfunction, liver and kidney dysfunction or bone marrow hematopoietic dysfunction; (3) patients with abnormal coagulation function; (4) patients with allergic constitution or allergic to the drugs involved in this trial; (5) patients with previous history of gastrointestinal bleeding and bleeding tendency; (6) patients with severe mental illness; (7) those who participated in other investigational drug or device clinical trials within the past 3 months; (8) other situations considered by the investigators to be inappropriate for this clinical study.

Design outcomes

Primary

MeasureTime frame
The lower limbs were examined by color Doppler ultrasound;Anemia indicators (Hb, Hct, MCV, MCH and MCHC);Coagulation indexes (D-dimer, APTT and PT);

Secondary

MeasureTime frame
Hidden blood loss;VAS score;HSS score;

Countries

China

Contacts

Public ContactHongmei Zhang

Wangjing Hospital of China Academy of Chinese Medicine Sciences

wangjingzhm@sina.com+86 139 1062 6823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026